Gao D, Gao X, Yang F, Wang Q
Int J Mol Sci. 2022; 23(15).
PMID: 35897734
PMC: 9332175.
DOI: 10.3390/ijms23158158.
Chu C, Li D, Chu C, Wu C, Lu T
Psychiatry Investig. 2018; 15(7):727-732.
PMID: 29898582
PMC: 6056701.
DOI: 10.30773/pi.2017.11.10.
Wang F, Zhang Y, Wang S, Zhang Y, Wu D, Zhang C
Oncotarget. 2017; 8(34):56021-56029.
PMID: 28915570
PMC: 5593541.
DOI: 10.18632/oncotarget.18715.
Skinner C, Ivanov N, Barr S, Chen Y, Skalsky R
J Virol. 2017; 91(21).
PMID: 28794034
PMC: 5640834.
DOI: 10.1128/JVI.00530-17.
Sturgeon J, Finan P, Zautra A
Nat Rev Rheumatol. 2016; 12(9):532-42.
PMID: 27411910
PMC: 5449457.
DOI: 10.1038/nrrheum.2016.112.
Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis.
Choulaki C, Papadaki G, Repa A, Kampouraki E, Kambas K, Ritis K
Arthritis Res Ther. 2015; 17:257.
PMID: 26385789
PMC: 4575443.
DOI: 10.1186/s13075-015-0775-2.
Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients.
Song S, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S
Arthritis Res Ther. 2013; 15(5):R141.
PMID: 24286116
PMC: 3978580.
DOI: 10.1186/ar4323.
Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties.
Issafras H, Corbin J, Goldfine I, Roell M
J Pharmacol Exp Ther. 2013; 348(1):202-15.
PMID: 24194526
PMC: 6067399.
DOI: 10.1124/jpet.113.205443.
Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics.
Ait-Oudhia S, Lowe P, Mager D
CPT Pharmacometrics Syst Pharmacol. 2013; 1:e5.
PMID: 23835885
PMC: 3603473.
DOI: 10.1038/psp.2012.6.
Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes.
Mandrup-Poulsen T
Rev Diabet Stud. 2013; 9(4):338-47.
PMID: 23804271
PMC: 3740701.
DOI: 10.1900/RDS.2012.9.338.
Anti-cytokine therapies in T1D: Concepts and strategies.
Nepom G, Ehlers M, Mandrup-Poulsen T
Clin Immunol. 2013; 149(3):279-85.
PMID: 23510726
PMC: 3700624.
DOI: 10.1016/j.clim.2013.02.003.
Management of hypersensivity pneumonitis.
Agache I, Rogozea L
Clin Transl Allergy. 2013; 3(1):5.
PMID: 23374544
PMC: 3585806.
DOI: 10.1186/2045-7022-3-5.
Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP).
Yilmaz-Elis A, Aartsma-Rus A, t Hoen P, Safdar H, Breukel C, van Vlijmen B
Mol Ther Nucleic Acids. 2013; 2:e66.
PMID: 23340324
PMC: 3564974.
DOI: 10.1038/mtna.2012.58.
Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.
Martin P, Bugelski P
Br J Pharmacol. 2011; 166(3):806-22.
PMID: 22168335
PMC: 3417411.
DOI: 10.1111/j.1476-5381.2011.01812.x.
A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases.
Sha Y, Markovic-Plese S
Self Nonself. 2011; 2(1):35-42.
PMID: 21776333
PMC: 3136902.
DOI: 10.4161/self.2.1.15639.
Innate immunity and the pathogenicity of inhaled microbial particles.
Wolff C
Int J Biol Sci. 2011; 7(3):261-8.
PMID: 21448336
PMC: 3065738.
DOI: 10.7150/ijbs.7.261.
Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
Kuemmerle-Deschner J, Ramos E, Blank N, Roesler J, Felix S, Jung T
Arthritis Res Ther. 2011; 13(1):R34.
PMID: 21356079
PMC: 3241378.
DOI: 10.1186/ar3266.
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases.
Owyang A, Issafras H, Corbin J, Ahluwalia K, Larsen P, Pongo E
MAbs. 2010; 3(1):49-60.
PMID: 21048425
PMC: 3038011.
DOI: 10.4161/mabs.3.1.13989.
Structural insights into the assembly and activation of IL-1β with its receptors.
Wang D, Zhang S, Li L, Liu X, Mei K, Wang X
Nat Immunol. 2010; 11(10):905-11.
PMID: 20802483
DOI: 10.1038/ni.1925.
An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX).
Jung N, Hellmann M, Hoheisel R, Lehmann C, Haase I, Perniok A
Clin Rheumatol. 2010; 29(10):1169-73.
PMID: 20532937
DOI: 10.1007/s10067-010-1504-5.
